抑制恶性细胞中的 RIPK1 可增强免疫疗法和放疗的效果。

RIPK1 inhibition in malignant cells potentiates immunotherapy and radiotherapy outcome.

机构信息

Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France.

Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France.

出版信息

Oncoimmunology. 2024 Dec 31;13(1):2425465. doi: 10.1080/2162402X.2024.2425465. Epub 2024 Nov 4.

DOI:10.1080/2162402X.2024.2425465

PMID:39585102

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11540075/

Abstract

Apoptosis, necroptosis and pro-inflammatory NF-κB-dependent signaling are repressed by receptor-interacting serine/threonine-protein kinase 1 (RIPK1). A recent paper in describes a small molecule inducing the proteolytic degradation of RIPK1. In preclinical experiments, this RIPK1 inhibitor improved the anticancer efficacy of radiotherapy, immunotherapy (with PD-1 blockade) and radioimmunotherapy (with CTLA-4 blockade).

摘要

细胞凋亡、坏死性凋亡和促炎 NF-κB 依赖性信号转导受到受体相互作用丝氨酸/苏氨酸蛋白激酶 1（RIPK1）的抑制。最近在中描述了一种小分子，可诱导 RIPK1 的蛋白水解降解。在临床前实验中，这种 RIPK1 抑制剂提高了放射治疗、免疫疗法（PD-1 阻断）和放射免疫疗法（CTLA-4 阻断）的抗癌疗效。